title: Tailoring access to high cost, genetically targeted drugs.
abstract: Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.
authors.forename: Wayne D
authors.initials: WD
authors.lastname: Hall
authors.forename: Robyn
authors.initials: R
authors.lastname: Ward
authors.forename: Winston S
authors.initials: WS
authors.lastname: Liauw
authors.forename: Christine Y
authors.initials: CY
authors.lastname: Lu
authors.forename: Jo-anne E
authors.initials: JA
authors.lastname: Brien
mesh_terms: D026683:Advisory Committees; D001315:Australia; D003219:Confidentiality; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D017277:Drug Approval; D016527:Drug Costs; D005380:Financing, Government; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D010597:Pharmacogenetics